Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision BioSciences is supported by a differentiated ARCUS platform that is already generating first clinical evidence of direct cccDNA elimination in HBV and is advancing a near full-length dystrophin strategy in DMD, giving it two high-conviction shots on goal in large, underserved markets. In ELIMINATE-B, 38 doses across 16 patients produced a 1-log reduction in cccDNA-derived transcripts, 6/6 baseline pgRNA-positive patients became undetectable, and HBsAg declined in 15/15 evaluable patients, while safety improved after infusion and steroid mitigation. The DMD program also shows meaningful preclinical de-risking, with over 20% skeletal-muscle restoration, durable gains to 9 months, and NHP transduction that equaled or exceeded mice, supporting a potentially best-in-class profile despite near-term development risk.

Precision BioSciences is weighed down by a highly speculative valuation framework that assumes only a 20% probability of success for PBGENE-DMD and 40% for the partnered allogeneic CD19CAR-T program, signaling substantial clinical and execution risk. The model also relies on ARCUS revenue beginning in 2030, which leaves a long gap before meaningful commercialization, while a 12% discount rate and 6.0x terminal EBITDA multiple underscore the uncertainty embedded in future cash flows. In addition, approximately $100M of gross equity raises in 2027E could dilute existing shareholders, limiting upside even if development progresses.